Launching the Alzheimer’s Disease Atlas at ADI2026 Conference
On 15 April, at the ADI Conference in Lyon, France, ADI shared the Alzheimer’s Disease Atlas, a first-of-its-kind website mapping the global landscape of Alzheimer’s disease.
News
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Featured news
ADI CEO delivers speech at French Ministry of Health ahead of ADI2026 Conference
Read the transcript of ADI CEO Paola Barbarino's full speech at the French Ministry of Health, in Paris, France, 10 April 2026.
The FDA sets priority review date for Lecanemab
Lecanemab is the second Alzheimer’s disease pharmaceutical treatment to come to market since 2003, following the conditional approval of Aduhlem (aducanumab) in June 2022.
Reflecting on 2022 and looking ahead to 2023
In this blog, members of the ADI team look back at 2022 and write about their hopes and aspirations for 2023.
Starting a conversation: Occupational therapy and dementia
In this blog, the authors of 'Occupational Therapy and Dementia' discuss the importance of occupational therapy in better supporting people living with dementia, as well as raising awareness about reducing the risk of dementia.
Shining a light on childhood dementia
Most people associate dementia with older adults; however, dementia can impact all age groups, including children.
Older persons and dementia organisations raise concerns relating to the new pandemic treaty
A joint letter was submitted in anticipation of the 3rd session of the World Health Organization's Intergovernmental Negotiating Body on 5-7 December.
Lecanemab results attract widespread international attention at CTAD
Eisai presented the results of their confirmatory Phase 3 clinical trial (CLARITY AD) at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Francisco, which many are hailing as positive news for the field.
Gantenerumab fails to meet primary goal
In a press release, Roche confirmed that the Phase 3 GRADUATE studies for gantenerumab did not meet their primary goal of slowing clinical decline in people with early Alzheimer’s disease.
Bringing the best to life at Summerset
In this blog from Orquidea Tamayo Mortera of Summerset, one of New Zealand’s leading independent retirement village operators, Orquidea writes about how Summerset is responding and rising to the evolving challenges of care for people living with dementia through innovative ways.